Gene Editing T-Cells to Fight CD7 Blood Cancers
This patent describes a method to treat specific blood cancers by using genetically modified T-cells that are engineered to attack cancer cells without harming themselves or triggering severe immune reactions in the patient.
Original patent title: “Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors”
This patent describes a method to treat specific blood cancers by using genetically modified T-cells that are engineered to attack cancer cells without harming themselves or triggering severe immune reactions in the patient. Granted to Washington University in St. Louis in 2026 with 31 claims, and it is expected to expire in 2045.
Coverage
What does this patent actually cover?
This patent outlines a method for treating CD7 positive hematologic cancers, which are types of blood cancer, in humans. It involves administering specially modified human T cells. These T cells are engineered to express a Chimeric Antigen Receptor (CAR) that specifically binds to a protein called CD7, which is found on the cancer cells (ClaimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1a). Crucially, these T cells have two genetic modifications: a first 'indel' (a small insertion or deletion) in their own CD7 gene, making them 'CD7 deficient' (Claim 1b), and a second indel in their T cell Receptor Alpha Chain (TRAC) gene, making them 'TRAC deficient' (Claim 1c). The CD7 modification prevents the CAR-T cells from attacking each other (a problem called fratricide, Claim 7), while the TRAC modification helps prevent the modified cells from attacking the patient's healthy tissues (called alloreactivity or Graft-versus-Host Disease, Claim 10). For example, this method could be used to treat T-cell acute lymphoblastic leukemia (T-ALL) by infusing these specially prepared T cells into a patient (Claim 11, 12).
The gap
What does this patent NOT cover?
- Does not cover CAR-T cells that target antigens other than CD7 (e.g., CD19 or BCMA).
- Does not cover CAR-T cells that lack a specific genetic modification (indel) in their own CD7 gene.
- Does not cover CAR-T cells that lack a specific genetic modification (indel) in their T cell Receptor Alpha Chain (TRAC) gene.
- Does not cover CAR-T cells where the genetic modifications are not 'indels' (e.g., gene insertions or point mutations).
- Does not cover methods for treating cancers that are not CD7 positive hematologic cancers.
- Does not cover CAR-T cells modified to prevent fratricide or alloreactivity through non-genetic means or different genetic targets.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The truly clever part is the dual genetic modification of the CAR-T cells themselves. By making the T-cells deficient in CD7, they become 'fratricide-resistant,' meaning they won't attack each other even while targeting CD7 on cancer cells. Simultaneously, disabling the T cell Receptor Alpha Chain (TRAC) prevents the engineered cells from causing harmful immune reactions against the patient's healthy body, a significant safety improvement.
The Patent Drawing

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
CAR-T cell therapies for blood cancers
Gene-edited cell therapies
Treatments for T-cell acute lymphoblastic leukemia (T-ALL)
Treatments for T-cell lymphoblastic lymphoma (T-LBL)
Treatments for T-cell non-Hodgkin's Lymphoma (T-NHL)
Why it matters
The bigger picture
Chimeric Antigen Receptor (CAR-T) cell therapy is a powerful new way to fight cancer, but it faces challenges, especially when targeting T-cell cancers because the cancer cells and the therapeutic T-cells often share surface markers like CD7. This patent addresses two major problems in CAR-T therapy: 'fratricide,' where the engineered T-cells attack each other, and 'alloreactivity,' where the T-cells attack healthy patient tissues. By genetically modifying the T-cells to be resistant to these issues, this invention aims to make CAR-T therapy safer and more effective for a wider range of blood cancers, specifically those that express CD7.
Filed
April 24, 2025
Granted
March 3, 2026
Market context
Who's building on this
Companies in this space
Washington University in St. Louis, as the assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →, is likely to be developing this specific technology further. In the broader field of CAR-T cell therapy and gene editing for cancer, major pharmaceutical companies like Novartis, Gilead Sciences, and Bristol Myers Squibb are active. Gene editing companies such as CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics are also working on similar approaches to modify cells for therapeutic purposes.
Market impact
This patent, once granted and if successfully developed, has the potential to significantly expand the market for CAR-T cell therapies. Currently, treating T-cell malignancies with CAR-T cells is challenging due to the risk of fratricide and alloreactivity. This invention could enable new, safer, and more effective treatments for these difficult-to-treat cancers, potentially creating a new category of 'universal' or 'off-the-shelf' CAR-T products with reduced side effects, thereby increasing patient access and market size.
Claim 1 — Plain English
What this patent covers
This patent outlines a method for treating CD7 positive hematologic cancers, which are types of blood cancer, in humans. It involves administering specially modified human T cells. These T cells are engineered to express a Chimeric Antigen Receptor (CAR) that specifically binds to a protein called CD7, which is found on the cancer cells (Claim 1a). Crucially, these T cells have two genetic modifications: a first 'indel' (a small insertion or deletion) in their own CD7 gene, making them 'CD7 deficient' (Claim 1b), and a second indel in their T cell Receptor Alpha Chain (TRAC) gene, making them 'TRAC deficient' (Claim 1c). The CD7 modification prevents the CAR-T cells from attacking each other (a problem called fratricide, Claim 7), while the TRAC modification helps prevent the modified cells from attacking the patient's healthy tissues (called alloreactivity or Graft-versus-Host Disease, Claim 10). For example, this method could be used to treat T-cell acute lymphoblastic leukemia (T-ALL) by infusing these specially prepared T cells into a patient (Claim 11, 12).
The clever bit
The truly clever part is the dual genetic modification of the CAR-T cells themselves. By making the T-cells deficient in CD7, they become 'fratricide-resistant,' meaning they won't attack each other even while targeting CD7 on cancer cells. Simultaneously, disabling the T cell Receptor Alpha Chain (TRAC) prevents the engineered cells from causing harmful immune reactions against the patient's healthy body, a significant safety improvement.
What it does not cover
- Does not cover CAR-T cells that target antigens other than CD7 (e.g., CD19 or BCMA).
- Does not cover CAR-T cells that lack a specific genetic modification (indel) in their own CD7 gene.
- Does not cover CAR-T cells that lack a specific genetic modification (indel) in their T cell Receptor Alpha Chain (TRAC) gene.
- Does not cover CAR-T cells where the genetic modifications are not 'indels' (e.g., gene insertions or point mutations).
- Does not cover methods for treating cancers that are not CD7 positive hematologic cancers.
- Does not cover CAR-T cells modified to prevent fratricide or alloreactivity through non-genetic means or different genetic targets.
Patent timeline
Application submitted to the patent office
Application published, typically 18 months after filing
Patent officially issued
Patent enters public domain
PatentBrief Score
Impact Score
Moderate
Citation count
0/40
No citations yet
Claim breadth
20/20
Very broad protection
Recency
20/20
Granted within 5 years
Assignee scale
0/20
Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$108K – $346K
Midpoint $216K · 18.4 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
The original legal language
Original claims
31 claims as filed with the patent office.
Concepts involved
Citations
Patent lineage
Cite this patent
Cooper, M., & DiPersio, J. F. (2026). Gene Editing T-Cells to Fight CD7 Blood Cancers (U.S. Patent No. 12,564,648). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/12564648/gene-editing-of-car-t-cells-for-the-treatment-of-t-cell-malignancies-with-chimer
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US12564648"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
Semantically similar
You might also find these interesting
US 9328156 · 2016 · University of Pennsylvania Penn
How Genetically Modified T-Cells Attack Cancer
US 9481728 · 2016 · University of Pennsylvania Penn
How Genetically Modified T-Cells Fight CD19 Cancers
US 12630603 · 2026 · Kite Pharma
Making Better CAR-T Cells to Fight Lymphoma
US 12600775 · 2026 · Kite Pharma
Treating a Specific Lymphoma with Modified T Cells
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does Gene Editing T-Cells to Fight CD7 Blood Cancers cover?
This patent describes a method to treat specific blood cancers by using genetically modified T-cells that are engineered to attack cancer cells without harming themselves or triggering severe immune reactions in the patient.
Who owns patent US 12564648?
Washington University in St. Louis owns this patent, granted in 2026.
When does this patent expire?
This patent is expected to expire on April 24, 2045, when the invention enters the public domain.
What problem does this patent solve?
Chimeric Antigen Receptor (CAR-T) cell therapy is a powerful new way to fight cancer, but it faces challenges, especially when targeting T-cell cancers because the cancer cells and the therapeutic T-cells often share surface markers like CD7. This patent addresses two major problems in CAR-T therapy: 'fratricide,' where the engineered T-cells attack each other, and 'alloreactivity,' where the T-cells attack healthy patient tissues. By genetically modifying the T-cells to be resistant to these issues, this invention aims to make CAR-T therapy safer and more effective for a wider range of blood…
What does this patent NOT cover?
Does not cover CAR-T cells that target antigens other than CD7 (e.g., CD19 or BCMA).
Patent monitoring




